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Neutralizing antibodies were raised in mice against notexin, the most toxic phospholipase 4 (PLA,) from Notechis cuta- 
tus scutatus venom, without the necessity of detoxifying the toxin prior to immunization. Using a sensitive radioimmuno- 
assay we demonstrated that anti-notexin antibodies recognized (i) the parent antigen, (ii) closely related isoforms of notex- 
in and (iii) venoms from Notechis genus snakes. In contrast, they failed to recognize other purified PLA, or PLA+ontain- 
ing venoms from other origins. Substitutions or chemical modifications occurring in the C-terminal part of the polypep- 
tide chain of notexin altered the binding affinity for antibodies, implying that this region constitutes an antigenic domain 
of notexin. 
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1. INTRODUCTION 
Presynaptic phospholipases A2 (PLA2) from 
snake venoms block acetylcholine release from 
nerve endings, induce efficient flaccid paralysis [l] 
and thus provoke fatal respiratory failure. They 
are toxic in humans [2] and serotherapy constitutes 
the most efficient antidote treatment [3]. 
Notexin from the Australian tiger snake 
Notechis scutatus scutatus [4] is a monomeric 
PLA2 with both presynaptic and myotoxic proper- 
ties [1,5,6]. Despite the clinical importance of 
notexin, few studies have been devoted to its im- 
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Notexin, notechis II-5 and notechis 11-l were purified from 
the venom of N. scutatus scutatus (Australian Reptile Park, 
Gosford, Australia), according to Karlsson et al. [4]. Notexin 
was further separated from an isoform called notechis Ns by 
reverse-phase high-performance liquid chromatography (RP- 
HPLC), as described [ft]. Other PLA2 were obtained as in [8]. 
2.2. Methods 
Abbreviations: PLA2, phospholipase AZ; RP-HPLC, reverse- Iodination with Na’251 (Oris Industries, France) using Iodo- 
phase high-performance liquid chromatography; OrNPhSCl, gen and modification by 2-nitrophenylsulfenyl chloride 
2nitrophenylsulfenyl chloride; PEG, poly(ethylene) glycol; (OzNPhSCl) were performed on notexin according to Fraker 
LDso, median lethal dose and Speck [9] and Scoffone et al. [lo], respectively. Resulting 
munological properties [2,3,7]. The purpose of this 
study was (i) to examine the ability of anti-notexin 
antibodies to neutralize notexin lethality and en- 
zymatic activity; (ii) to investigate the ability of an- 
tibodies to recognize a large range of purified 
PLA2 and snake venoms containing PLA2; and 
(iii) to identify antigenic domain(s) of notexin. The 
present data may be of importance for the design 
of more efficient protective antisera against notex- 
in and related toxins. 
2. MATERIALS AND METHODS 
2.1. Materials 
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derivatives of notexin were purified by RP-HPLC (Mollier et 
al., submitted). 
For radioimmunoassays, 100/A highly purified 12~l-labelled 
monoiodinated notexin (20000cpm/assay,  3.7 TBq/mmol)  
was incubated overnight at 4°C with 100/A antibody solution, 
100/zl of  purified unlabelled analogs or crude snake venoms 
dilutions, and 10/A horse serum. 300/A of a 20°7o poly(ethylene) 
glycol (PEG) 6000 solution was added and the mixture was cen- 
trifuged at 1000 x g for 30 min. Radioactivity in the pellets was 
measured in a gamma counter (LKB, Bromma, Sweden). 
Immunized BALB/c mice received successively one in- 
travenous injection of a sublethal dose of notexin (0.25/zg/20 g
mouse) in physiological saline, three subcutaneous injections, 
one per week, of 0.30/zg/20g mouse of notexin in 
physiological saline, and four subcutaneous injections, one per 
week, of increasing doses of notexin (from 10 to 75/zg) in 
physiological saline mixed with Freund's incomplete adjuvant 
(Difco, Detroit, MI) (5 : 3, v/v). Three days after the booster in- 
jection of  notexin (75/~g), 3 × l0 s Ehrlich tumor cells were in- 
jected intraperitoneally into the mice. Ascitic fluids containing 
polyclonal antibodies were precipitated with ammonium 
sulfate, then dialyzed three times for 24 h against 20 mM Tris- 
HC1 (pH 7.7). 
For toxicity measurements, native notexin was injected into 
the tail vein of four BALB/c mice IFFA CREDO (Lyon, 
France) (weight 20 _+ 2 g), in the presence and absence of a 
200-fold molar excess of antibodies. Mice were examined 24 h, 
48 h and 1 week after injection. 
Enzymatic activity was determined using a titrimetric method 
[11] with a Methrm pH-stat. Egg yolk phosphatidylcholine 
(type IX-E, Sigma) was sonicated under a nitrogen atmosphere 
for 30 min and then mixed with sodium deoxycholate in a molar 
ratio of  1 : 3.7. The final concentration of substrate was 45 mM 
in 20 mM CaClz, 120 mM NaCI and notexin concentrations 
varied between 0 and 9.2 nM. The assay volume was 4 ml and 
the reaction was monitored by addition of 10 mM NaOH, at 
pH 8.0 and 40°C. Antibodies used for enzymatic assays were 
dialysed three times for 24 h against 20 mM CaC12, 120 mM 
NaCI. 
3. RESULTS AND DISCUSSION 
3.1. Radioimmunoassay nd properties of anti- 
notexin antibodies 
Using Iodo-gen as a mild oxidizing agent [9], we 
prepared monoiodinated notexin with a specific 
activity equal to 1.8 or 3.7 TBq/mmol. We observ- 
ed that native and mono-iodinated notexin (i) had 
virtually superimposable far-ultraviolet circular 
dichroic spectra (not shown) and (ii) had respective 
LDso equal to 0.34 + 0.03 and 0.38 _ 0.04/zg per 
20 g mouse. Clearly, iodination had not altered the 
structural and basic biological properties of 
notexin. 
In order not to bias the immunological response, 
we carefully avoided injecting detoxified notexin 
during the immunological procedure and 
therefore, mice received native notexin alone using 
low antigen doses. Nevertheless, antibody titers 
routinely reached 1/500-1/800, using 125I-labelled 
notexin of specific activity 3.7 TBq/mmol (titer is 
defined as the serum dilution that binds half of 
total radioactivity). Precipitation of antigen- 
antibody complexes using poly(ethylene) glycol 
gave a mean standard variation equal to + 3 °7o and 
non-specific binding varied between 5 and 10°70 of 
the total radioactivity added in each assay. 
Anti-notexin antibodies specifically abolished 
the lethal activity and greatly affected the en- 
zymatic activity of notexin (table 1). However, en- 
zymatic activity was never abolished completely, 
even in the presence of a large excess of antibodies. 
Approx. 4°7o of the original activity remained. 
Similarly, Caratsch et al. [12] reported that ap- 
prox. 10°70 of the original enzymatic activity of ~'- 
bungarotoxin persisted in the presence of a large 
excess of polyclonal anti-~-bungarotoxin an- 
tibodies. The reason for this residual enzymatic ac- 
tivity is presently unclear. 
3.2. Competition data 
Natural isoforms as well as two chemically 
modified derivatives of notexin competed with 
~25I-labelled notexin for binding to anti-notexin 
Effect 
Table 1 
of polyclonal antibodies on in vivo toxicity and 
enzymatic activity of notexin 
Compound Percent Enzymatic 
survival activity 
in mice (/amol/min) 
Notexin 0 a 7360 e
Notexin + polyclonal antibodies 100 b 311 f 
Polyclonal antibodies 100 c N.D. 
Notexin + M71 N.D. 7360 g
Tris buffer (20 mM, pH 7.7) 100 a N.D. 
a0.6/~g (44pmol) notexin in 150/~1 saline was injected 
intravenously in four BALB/c mice (LD10o value of notexin = 
0.5,ug/20 g mouse). 8.8 nmol anti-notexin antibodies were 
incubated overnight in the presence (b) or absence (c) of notexin 
prior to injection; d the effect of the buffer was also examined; 
e the enzymatic activity was defined as the amount of substrate 
(in/zmol) hydrolyzed per min and per/zmol of enzyme at 40°C 
and pH 8.0; f polyclonal antibodies were used in a 200-fold 
molar excess over notexin, g M'rl is an unrelated monoclonal 
antibody; M7~ was used in a 200-fold molar excess over 
notexin. N.D., not done 
480 
Volume 250, number 2 FEBS LETTERS July 1989 
100 . , - , , - ,  . . . . . . . . .  I . . . . . . . .  i . . . . . . . .  I . . . . . . . .  
00.1  ° . . . . . . . .  i . . . . . . . .  i . . . . . . .  .~" - . , .~  . . . . .  ~ . . . . . .  
lo ~ lo" to "7 10 "6 lo 5 
[COMPET ITOR I | 54)  
Fig.1. Experiments illustrating competition between 125I -  
labelled notexin (3.7 TBq/mmol) and notexin (r~), notechis Ns 
(+), notexin mono-NPhS (A) and notexin di-NPhS-derivative 
(o) for binding to anti-notexin antibodies (1:500). B/Bo was 
determined as the ratio (07o) of radioactivity bound by 
antibodies in the presence (B) and absence (Bo) of competitor. 
ant ibodies (fig. 1). As shown in table 2 the binding 
aff init ies of  notechis Ns and notechis II-5 were 
similar,  if  not identical to that of  notexin, a l though 
they have one (posit ion 16) and eight (posit ions 16, 
20, 31, 47, 53, 54, 56 and 62) substitut ions, respec- 
tively [13]. It is l ikely therefore that all these posi- 
t ions are excluded as major  antigenic determinants 
o f  notexin. In contrast,  concomitant  incorporat ion 
o f  a ni trophenyl  moiety via a thioether bond at the 
C-2 posit ion of  the indole ring of  Trp-20 and 
Trp-110 led to a derivative, referred to as d i -NPhS-  
notexin,  which was recognized with weaker aff ini-  
ty. Previous work showed that modi f icat ion of  
both t ryptophans did not affect the overall  ar- 
chitecture of  notexin (Moll ier et al., submitted).  
Since posit ion 20 o f  notexin could be substituted in 
notechis II-5 (Trp is replaced by Arg) or  modi f ied 
with a n i t rophenyl  moiety without affecting bind- 
ing aff in i ty (table 2), we conclude that the altera- 
t ion of  antigenicity observed with d i -NPhS-notexin 
was essential ly due to modi f icat ion of  Trp 110. 
The data,  therefore,  strongly suggest hat a critical 
antigenic area is located at, or in prox imity  to Trp 
110, i.e. in the C-terminal  region of  the notexin 
po lypept ide chain, a region which was proposed to 
be crit ical for the toxic activity in the case of  both 
the PLA2 f rom Vipera ammodytes  [14] and notex- 
in (Mol l ier et aI., submitted).  Notechis II-1 har- 
bored as many as 40 substitut ions [15] but 
nevertheless displayed substantial ,  though reduc- 
ed, af f in i ty for ant i -notexin ant ibodies (table 2). 
Pos i t ion 110 was substituted in notechis II-1, thus 
of fer ing an explanat ion for its decrease in an- 
t igenicity. 
Table 2 
Competition between ~2~I-notexin a d different PLA2 or 
venoms for anti-notexin polyclonal antibodies 
ICso 
Purified phospholipases A2 (nM) 
Notexin (Notechis cutatus cutatus) 5,0 
Notechis Ns (N. scutatus cutatus) 5.0 
Notexin modified at Trp-20 5.0 
Notechis II-5 (N. scutatus cutatus) 7.0 
Notechis II-I (N. scutatus cutatus) 25.0 
Notexin modified at Trp-20 and Trp-110 37.0 
Nigexine (Naja nigricollis) > 1000 
Na. nigricollis acidic PLA2 > 1000 
Na. mossambica mossambica CM III > 1000 
Na. mossambica mossambica CM II > 1000 
/Y-Bungarotoxin (Bungarus multicinctus) > 1000 
Crotoxin CA subunit (Crotalus durissus 
terrificus) > 1000 
Crotoxin CB subunit (C. durissus terrificus) > 1000 
C. durissus durissus PLA2 > 1000 
C. adamanteus PLA2 > 1000 
Bee venom PLA2 > 1000 
Porcine pancreatic PLA2 > 1000 
Crude venoms (ug/ml) 
N. scutatus cutatus 0.3 
N. ater kangaroo 0.3 
N. ater ater 0.4 
N. ater serventyi 2.4 
N. occidentalis 760 
Pseudonaja nuchalis > 20000 
Pa. butleri > 16000 
Hoplocephalus stephensii > 20 000 
Acantophis antarticus 4000 
A. barkley > 20 000 
Oxyuranus cutellatus > 20000 
Na. melanoleuca melanoleuca > 20000 
Na. haje (Mali) >20000 
Na.. oxiana > 20 000 
Hemachatus haemachatus > 20000 
Micrurus corallinus > 20000 
Laticauda laticaudata > 20000 
Aipysurus laevis > 20000 
Vipera russelli > 20000 
Agkistrodon rhodostoma >20000 
Bitis arietans >20000 
C. adamenteus > 20000 
Specific radioactivity of ~25I-notexin was 3.7 TBq/mmol; 
polyclonal antibodies were used at a concentration 
corresponding to the titer (1:200); IC50, concentration of 
competitor (purified proteins or crude venoms) which inhibits 
50070 of the binding of ~25I-notexin to polyclonal antibodies 
As shown also in table 2, other puri f ied PLA2 
f rom land and sea snakes venoms, bee venom and 
mammal ian  pancreas failed to compete with 125I- 
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labelled notexin for binding to anti-notexin an- 
tibodies. Examination of amino acid sequences 
[16] revealed that these PLA2 harbor more than 50 
substitutions including some in the C-terminal 
area, but we do not yet know which particular 
substitution(s) render(s) the PLA2 unrecognizable 
by anti-notexin antibodies. 
To investigate the specificity of the anti-notexin 
antibodies further, we also examined their ability 
to recognize 22 different snake venoms (table 2). 
The few venoms that contained components an- 
tigenically related to notexin were from snakes of 
the Notechis genus and, to a substantially esser ex- 
tent, the venom of the Australian snake Acan- 
tophis antarticus. All other venoms, many of 
which are known to contain PLA2, were 
unrecognized by anti-notexin antibodies, even 
when added in large excess. 
The present paper conclusively demonstrates 
that anti-notexin antibodies from mice (i) are 
capable of neutralizing notexin activity; (ii) are 
highly specific for notexin and closely related 
homologs and (iii) recognize the highly variable C- 
terminal polypeptide chain as an antigenic region. 
Because of their narrow specificity, mouse anti- 
notexin antibodies are unlikely to offer significant 
protection against other presynaptic PLA2. 
In the course of the last decade, a number of 
studies have been devoted to the study of the im- 
munological properties of various presynaptic 
PLA2 [17]. These toxins include g-bungarotoxin 
from Bungarus multicinctus [18], crotoxin from 
Crotalus durissus terrificus [19,20] and taipoxin 
from Oxyuranus cutellatus scutellatus [21]. These 
studies indicated that poly- and monoclonal an- 
tibodies raised against hese toxins are specific for 
the parental antigens. Our observations, therefore, 
are in support of this being a general property of 
anti-presynaptic PLA2 antibodies. This conclusion 
is all the more interesting as Minton [22] reported, 
some years ago, that antiserum to tiger snake 
venom was exceptionally efficient at neutralizing 
other venoms. Conceivably, the broad specificity 
of antiserum against the venom of N. scutatus 
scutatus might be due to antibodies raised against 
notexin homologs present in the venom, such as 
LETTERS July 1989 
notechis II-1 [15] as suggested by recent ex- 
periments of Nicholson et al. [23]. 
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